Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA grants accelerated approval to Amondys 45 for Duchenne muscular dystrophy

Feb. 26, 2021

Intra-Cellular plans to develop ITI-1284 for dementia and depressive disorders in the elderly

Feb. 26, 2021

Phase IIb interim data on mirdametinib in NF1-associated plexiform neurofibromas

Feb. 25, 2021

New model developed for testing drugs for Nav1.9-related neuropathic pain

Feb. 25, 2021

Benitec reports interim data on pilot dosing study of BB-301 for OPMD

Feb. 25, 2021

New phase II trial evaluates BIVV-020 in chronic inflammatory demyelinating polyneuropathy

Feb. 25, 2021

Intracranial samples give glimpse into stroke response

Feb. 25, 2021

Nanoform reports further data from phase I study of Nanoformed piroxicam

Feb. 24, 2021

FDA clears IND for pilot study of NT-17 in progressive multifocal leukoencephalopathy

Feb. 24, 2021

Calpain-2 inhibition as a promising approach for treating seizure-induced neuropathology

Feb. 24, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...